| 摘要 |
PROBLEM TO BE SOLVED: To provide a solid pharmaceutical dosage form providing improved oral bioavailability for inhibitors of HIV protease.SOLUTION: A solid pharmaceutical dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50°C and at least one pharmaceutically acceptable surfactant, having an HLB value of from about 4 to about 10. The surfactant is sorbitan fatty acid ester. The water-soluble polymer is a homopolymer of N-vinyl pyrrolidone or a copolymer of N-vinyl pyrrolidone and vinyl acetate. |
